Twist Bioscience TWST Rallies As Guidance And Capital Raise Reset The Bar

Twist Bioscience Corporation stocks have been trading up by 16.14 percent following highly positive sentiment around its latest developments.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Q3 revenue hit $118.4M versus $114.54M expected, up over 23% year over year, but the EPS loss widened to ($0.56), keeping profitability in focus for TWST traders.
Management guided Q4 revenue to $123M–$124M, above roughly $117.4M–$117.42M consensus, and is targeting adjusted EBITDA breakeven as a near-term inflection.
Full-year FY26 revenue guidance increased to $456M–$457M with gross margin now seen above 52%, signaling Twist Bioscience aims to scale with better unit economics.
TD Cowen and Baird lifted their TWST price targets to $115 with Buy/Outperform ratings, leaning into Q3 strength and triple-digit AI-enabled drug discovery order growth expected in FY27.
An upsized $300M equity offering at $96 per share adds growth capital for TWST R&D, manufacturing, and product build-out, but also introduces fresh dilution for traders to weigh.

Quick Financial Overview

Twist Bioscience, trading under ticker TWST, has been on a sharp upswing. The stock closed at $115.01 on 2026/08/05, after tagging an intraday high of $115.56. Just two sessions earlier, TWST had finished at $101.06, and it was under $90 several days before that. For active traders, that is a textbook momentum push off a catalyst.

The catalyst is clear. TWST posted Q3 revenue of $118.4M, beating the roughly $114.5M consensus and growing more than 23% year over year. At the same time, the company’s loss widened to ($0.56) per share, reminding the market this is still a growth story, not a profit machine yet.

On the tape, TWST shows strong intraday support building in the low $110s, with repeated bounces between $111 and $113 throughout the afternoon before a late push back toward the highs. That kind of staircase pattern often tells traders that dip buyers are in control.

More Breaking News

Fundamentals back up the action. TWST runs gross margin around 52%, but EBIT and net margins remain negative, with return on equity and assets solidly below zero. Cash on hand, a current ratio near 2.7, and a modest debt load give it room to keep funding growth. For traders, the message is simple: this is a classic high-growth, high-valuation, still-loss-making biotech platform that trades on execution and guidance more than on current earnings.

Why Traders Are Watching TWST Now

Twist Bioscience has thrown a lot at the market in a short window, and that’s exactly when TWST becomes a prime trading vehicle. The Q3 print put the stock on screens: $118.4M in revenue, more than 23% year-over-year growth, and a clean beat versus expectations. But the bigger story for TWST is what comes next, not what just happened.

Management raised Q4 revenue guidance to $123M–$124M, well ahead of the roughly $117M Street view, and told traders to expect adjusted EBITDA breakeven. For a name like TWST that has run with heavy operating losses, that “breakeven” language matters. It signals a possible turning point where the company is no longer just burning cash to chase growth.

Then came the FY26 update. Twist Bioscience lifted revenue guidance to $456M–$457M, above the prior $442M–$447M range and comfortably above consensus around $444M–$446M. TWST also now sees gross margin above 52%, pointing to better operating leverage as volumes scale. For growth traders, higher sales with better margins is the sweet spot.

Wall Street has taken notice. TD Cowen bumped its TWST price target from $89 to $115 and reiterated a Buy rating, highlighting the revenue beat, the guidance raise, and expectations for another year of triple-digit AI-enabled drug discovery order growth in FY27. Baird followed, pushing its TWST target to $115 with an Outperform call. Another Cowen note pointed out that TWST was trading near $95.66 and up about 4.5% on the upgrade, even after early weakness when the wider loss first hit.

Yet the path has not been straight up. TWST traded down about 6.3% pre-market on earnings day, showing how traders initially focused on the bigger loss and prior run-up. That mismatch between fundamentals improving and knee-jerk price action is where short-term traders often find opportunity.

Layered on top of all this, Twist Bioscience launched an upsized $300M underwritten public offering at $96 per share, with extra shares available to the underwriters. That means dilution, which can pressure TWST near term. But it also means fresh cash for R&D, manufacturing expansion, and new products—fuel for the growth story that analysts are backing. The company also granted 44,434 RSUs to 24 new hires, a small signal that TWST is still building its team and infrastructure.

Conclusion

For active traders, TWST is now a battle between short-term dilution fears and a steadily improving growth path. On one side, Twist Bioscience is still posting negative margins, with EBITDA around -$28M and net losses north of $35M in the latest quarter. Key profitability ratios—return on assets, return on equity—are all deeply negative. Those numbers explain why some traders sold the Q3 headline despite the revenue beat.

On the other side, the story around TWST is getting cleaner. Revenue is beating expectations. Q4 guidance is higher, with adjusted EBITDA breakeven targeted. FY26 revenue is set in the mid-$450M range with gross margin above 52%, and analysts at TD Cowen and Baird are crowding around a $115 target with Buy and Outperform ratings. Add in triple-digit AI-enabled drug discovery order growth expected in FY27, and TWST is sitting squarely in two hot themes: synthetic biology and AI-driven drug discovery.

The $300M equity raise at $96 per share gives Twist Bioscience more runway to try to hit those goals, even if existing holders take a hit from dilution. Short-term charts show strong momentum and active dip buying, but this is still a volatile, news-driven name. This is where disciplined preparation becomes crucial for anyone trading TWST’s swings rather than reacting emotionally to headlines. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” That mindset lines up well with the need to map key levels, catalysts, and potential dilution effects before the market opens.

As Tim Sykes likes to tell traders, “Patterns repeat, but you have to be prepared when they do.” With TWST, the pattern is a familiar one: high-growth biotech raising cash, tightening its path toward profitability, and whipping around every time guidance or analyst views change. For traders using this purely for educational and research purposes, the lesson is to track the levels, respect the volatility, and let the numbers—not the hype—drive your trading plan.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!